bms-986036
Recombinant proteinexperimental
Clinical trial activity
12 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2014 (NCT02097277)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor 21Supplementation
FGF21 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bms-986036
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04649710 | Phase 1 | Dec 15, 2020 | Bristol-Myers Squibb |
| NCT04634149 | Phase 1 | Nov 16, 2020 | Bristol-Myers Squibb |
| NCT04493567 | Phase 1 | Jul 29, 2020 | Bristol-Myers Squibb |
| NCT03674476 | Phase 2 | Sep 11, 2018 | Bristol-Myers Squibb |
| NCT03611101 | N/A | May 4, 2018 | Bristol-Myers Squibb, Meridien Research |
| NCT03486899 | Phase 2 | May 4, 2018 | Bristol-Myers Squibb |
| NCT03486912 | Phase 2 | May 4, 2018 | Bristol-Myers Squibb |
| NCT03445208 | Phase 1 | Feb 14, 2018 | Bristol-Myers Squibb |
| NCT03198182 | Phase 1 | Jun 28, 2017 | Bristol-Myers Squibb |
| NCT03400163 | Phase 2 | May 8, 2015 | Bristol-Myers Squibb |
| NCT02413372 | Phase 2 | May 8, 2015 | Bristol-Myers Squibb |
| NCT02097277 | Phase 2 | Apr 1, 2014 | Bristol-Myers Squibb |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 12 | 11 | 3 | 2014 |
| Meridien Research | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1